Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms – Impact Of Comorbidity

References

• SH S, Campo E, NL H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4 Lyon: International Agency for Research on Cancer (IARC); 2008.
   Google Scholar
• Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124(19):3021–3023. doi:10.1182/blood-2014-07-59161025377561
   PubMed Web of Science ®Google Scholar
• McMullin MF, Wilkins BS, Harrison CN. Management of polycythaemia vera: a critical review of current data. Br J Haematol. 2016;172(3):337–349. doi:10.1111/bjh.1381226492433
   PubMed Web of Science ®Google Scholar
• Harrison CN, Garcia NC. Management of MPN beyond JAK2. Hematology Am Soc Hematol Educ Program. 2014;2014(1):348–354. doi:10.1182/asheducation-2014.1.34825696878
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–173. doi:10.1002/ajh.2389525611051
   PubMed Web of Science ®Google Scholar
• Barbuil T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069. doi:10.1038/s41375-018-0077-129515238
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–1881. doi:10.1038/leu.2013.16323739289
   PubMed Web of Science ®Google Scholar
• Cerquozzi S, Barraco D, Lasho T, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7:66229282357
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446–2452. doi:10.1182/blood-2006-08-04251517105814
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–5859. doi:10.1182/blood-2011-02-33900221490340
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–2513. doi:10.1182/blood-2014-05-57913625037629
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Wilkes SR, Kristinsson SY, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol. 2015;33(20):2288–2295. doi:10.1200/JCO.2014.57.665226033810
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–2232. doi:10.1200/JCO.2005.07.06215710945
   PubMed Web of Science ®Google Scholar
• Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19(3):617–633. doi:10.1016/j.beha.2005.07.01116781491
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from european leukemianet. J Clin Oncol. 2011;29(6):761–770. doi:10.1200/JCO.2010.31.843621205761
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Bjorkholm M, Dickman PW, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168(5):317–325.29335713
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-324965263
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi:10.2147/CLEP.S9112526604824
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591. doi:10.2147/CLEP.S17908331372058
   PubMed Web of Science ®Google Scholar
• Norgaard M, Skriver MV, Gregersen H, Pedersen G, Schonheyder HC, Sorensen HT. The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry. Eur J Cancer Prev. 2005;14(3):201–206. doi:10.1097/00008469-200506000-0000215901987
   PubMed Web of Science ®Google Scholar
• Heide-Jorgensen U, Adelborg K, Kahlert J, Sorensen HT, Pedersen L. Sampling strategies for selecting general population comparison cohorts. Clin Epidemiol. 2018;10:1325–1337. doi:10.2147/CLEP30310326
   PubMed Web of Science ®Google Scholar
• Luhdorf P, Overvad K, Schmidt EB, Johnsen SP, Bach FW. Predictive value of stroke discharge diagnoses in the Danish National Patient Register. Scand J Public Health. 2017;45(6):630–636. doi:10.1177/140349481771658228701076
   PubMed Web of Science ®Google Scholar
• Sundboll J, Adelborg K, Munch T, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open. 2016;6(11):e012832. doi:10.1136/bmjopen-2016-012832
   PubMed Web of Science ®Google Scholar
• Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjonneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol. 2010;63(2):223–228. doi:10.1016/j.jclinepi.2009.03.01819595569
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83. doi:10.1186/1471-2288-11-8321619668
   PubMed Web of Science ®Google Scholar
• Belot A, Remontet L, Launoy G, Jooste V, Giorgi R. Competing risk models to estimate the excess mortality and the first recurrent-event hazards. BMC Med Res Methodol. 2011;11:78. doi:10.1186/1471-2288-11-7821612632
   PubMed Web of Science ®Google Scholar
• Hernan MA. The hazards of hazard ratios. Epidemiology. 2010;21(1):13–15. doi:10.1097/EDE.0b013e3181c1ea4320010207
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118(25):6515–6520. doi:10.1182/blood-2011-04-34875522039256
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. doi:10.1056/NEJMoa120850023216616
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27(10):2084–2086. doi:10.1038/leu.2013.20723828261
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–318. doi:10.3324/haematol.2010.03107021173097
   PubMed Web of Science ®Google Scholar
• Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134(5):469–479. doi:10.1182/blood.201900111331217187
   PubMed Web of Science ®Google Scholar